Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 22,255 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Heart Failure, Quality of Life
Interventions: Problem-Solving Treatment, Time Management; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Metapneumovirus
Interventions: Lumicitabine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Fresno, California • Long Beach, California • Eustis, Florida + 4 more

Conditions: ADME
Interventions: Controlled dietary background, (-)-[2-14C]epicatechin intake; Other
Lead sponsor: The Institutes for Pharmaceutical Discovery, LLC; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Juvenile Myopia
Interventions: Novel spectacle lens design, Spectacle lenses; Device
Lead sponsor: SightGlass Vision, Inc.; Industry
Eligibility: 6 Years to 10 Years
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 13
States / cities: Whittier, California • Longwood, Florida • Pensacola, Florida + 10 more

Conditions: Pain, Postoperative
Interventions: Intercostal Nerve Cryoablation, Bupivacaine liposomal injectable suspension, Patient-controlled analgesia (PCA); Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chemotherapy-induced Diarrhea
Interventions: SK10, Placebo; Drug
Lead sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Interventions: MEDI3902 - Dose 1, MEDI3902 - Dose 2, MEDI3902 - Dose 3, MEDI3902 - Dose 4, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation; Drug · Radiation
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more

Conditions: Phenylketonurias
Interventions: PreKUnil® LNAA Medical Food for PKU; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Pain
Interventions: OPY interactive messaging service, Standard care; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3,442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Mild Cognitive Impairment
Interventions: SAMSTAR, RAVLT; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 84 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Pneumonia, Diabetes, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions: Social Incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Traumatic Amputation of Lower Extremity
Interventions: FES; Device
Lead sponsor: Alicia Koontz; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Graves' Disease
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Glendale, Arizona • Los Angeles, California • San Jose, California + 11 more

Conditions: Bladder Cancer
Interventions: Polyphenon E, erlotinib hydrochloride, Erlotinib placebo, Polyphenon E; Dietary Supplement · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more

Conditions: Dermatomyositis, Myositis
Interventions: Empasiprubart IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Oceanside, California • DeBary, Florida • Gainesville, Florida + 6 more

Conditions: Restless Legs Syndrome, Iron Deficiency Anemia
Interventions: Ferumoxytol intravenous, Ferrous sulfate; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Glendale, California • Lemon Grove, California • Long Beach, California + 29 more

Conditions: Fibromyalgia
Interventions: Transcutaneous Vagus Nerve Stimulation; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COPD
Interventions: Zofin, Placebo; Drug · Other
Lead sponsor: ZEO ScientifiX, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cochlear Implants
Interventions: Cochlear Implants; Device
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 19 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Multiple Myeloma
Interventions: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more

Search by objective public record fields.

Improving Quality of Life in Heart Failure

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

Control of Myopia Using Novel Spectacle Lens Designs

Intercostal Nerve Cryoablation for Postoperative Pain Management

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)

The Implementation of a Post-operative Communication App to Improve Pain Control and Opioid Use

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Social Incentives to Increase Mobility

Functional Electrical Stimulation Use in Trans-tibial Amputations

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression

Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

Stream Segregation and Speech Recognition in Noise in Individuals With Cochlear Implants

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)